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Abstract
Background: The incidence of insomnia and depression in the elder population is significant. It is
hoped that use of light treatment for this group could provide safe, economic, and effective rapid
recovery.
Methods: In this home-based trial we treated depressed elderly subjects with bright white (8,500
Lux) and dim red (<10 Lux) light for one hour a day at three different times (morning, mid-wake
and evening). A placebo response washout was used for the first week. Wake treatment was
conducted prior to the initiation of treatment, to explore antidepressant response and the
interaction with light treatment. Urine and saliva samples were collected during a 24-hour period
both before and after treatment and assayed for aMT6s and melatonin respectively to observe any
change in circadian timing. Subjects wore a wrist monitor to record light exposure and wrist
activity. Daily log sheets and weekly mood (GDS) and physical symptom (SAFTEE) scales were
administered. Each subject was given a SCID interview and each completed a mood questionnaire
(SIGH-SAD-SR) before and after treatment. Also, Hamilton Depression Rating (SIGH-SAD
version) interviews were conducted by a researcher who was blind to the treatment condition. A
control group of healthy, age-matched, volunteers was studied for one day to obtain baseline data
for comparison of actigraphy and hormone levels.
Results:  Eighty-one volunteers, between 60 and 79 years old, completed the study. Both
treatment and placebo groups experienced mood improvement. Average GDS scores improved 5
points, the Hamilton Depression Rating Scale (HDRS) 17 scores (extracted from the self-rated
SIGH-SAD-SR) improved 6 points. There were no significant treatment effects or time-by-
treatment interactions. No significant adverse reactions were observed in either treatment group.
The assays of urine and saliva showed no significant differences between the treatment and placebo
groups. The healthy control group was active earlier and slept earlier but received less light than
the depressed group at baseline.
Conclusion:  Antidepressant response to bright light treatment in this age group was not
statistically superior to placebo. Both treatment and placebo groups experienced a clinically
significant overall improvement of 16%.
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Background
Several reviews have emphasized the enormous socioeco-
nomic impact in elders of insomnia and depression which
are often intertwined [1-5]. Reasons for depression in
elders include: loss of body strength, health and auton-
omy, loss of loved ones and friends, loss of occupational
status, and fear of impending death [6-8]. Some years ago,
the suicide rate was thought to be low among the oldest
adults, but this rate has been rising [9,10], despite the
improved financial condition of the over-60 population.
Antidepressant drugs are reasonably effective in older
patients, but depression often is inadequately-treated or
chronic. In elders, there is a greater risk of medication side
effects such as falls, over-sedation, and anti-cholinergic
disturbances [11,12]. These difficulties point to the poten-
tial usefulness of light treatment for depressed elders
either to supplement or replace pharmacotherapy. Devel-
opment of new light treatments could have widespread
benefit for millions of aging Americans with insomnia
and depression.
Light treatment for seasonal depression (SAD) has
become accepted in the Clinical Practice Guidelines
issued by the U.S. Department of Health and Human
Services [13] and the American Psychiatric Association's
Treatment of Psychiatric Disorders [14]. It is gratifying to see
this safe, inexpensive, rapid and effective treatment
spreading worldwide into clinical practice. Fewer light
treatment studies have been conducted to investigate non-
seasonal major depressions, but light is effective for non-
seasonal depression [15]. In nonseasonal depression,
light treatment may produce as much incremental benefit
or more when antidepressant drugs are also administered
[15]. There has been little formal study of light treatment
in the elderly, partly because seasonal depression seems
less common among women after menopause [16].
Several small studies have suggested promising results
with bright-light treatment of elderly patients who have
distinctive phase-advanced sleep disturbances [17], or
with dementia [18-22], but there has been little critical
examination of the value of bright light for the majority of
elderly Americans with less specific mood or sleep com-
plaints.
The mechanisms by which light produces antidepressant
effects are of essential scientific interest, both for under-
standing the underlying etiologies of depressive illnesses
and for guiding our treatment strategies. There is consid-
erable evidence that morning light is better than evening
light for SAD [15,23-26], but some studies have found lit-
tle difference between timings [27,28], and the apparent
advantage of morning light may be partly explained by an
anomalous order effect in cross-over designs [29]. When
morning light is effective, it might work by suppressing or
phase-advancing an overly-late melatonin offset [30-32].
It seems possible (though unproven) that conditions in
which sleep complaints are most prominent and condi-
tions in which mood complaints are most prominent
might have a common etiology in circadian phase mal-
synchronization which is characterized by abnormal
entrainment of circadian rhythms to the solar day and/or
abnormal relationships among rhythms in the body.
Phase-typing as a predictor of light-treatment response
was proposed by Lewy and colleagues [33] and has been
previously employed to select light treatment timing pro-
spectively [34]. We used this method in the belief that
without phase-typing and individualized treatment
assignment, sub-optimal results would be obtained.
Our early studies [35,36] the Praskos' study [37], and
especially the work of Neumeister et al. [38], Loving [39],
and Bloching [40] suggested that partial sleep deprivation
combined with bright light produces remarkable antide-
pressant responses, as demonstrated by dramatic contrasts
between bright light and placebo. Considering the evi-
dence that sleep deprivation may tend to accentuate the
contrast of bright light and placebo, we expected partial
sleep deprivation would add to the potential effectiveness
of individual timed light therapy.
In this paper, we report on a clinical trial of bright light
treatments in the home, with individualized treatment
timing. The goals of the study were to determine if light
resistance in the 60–79 year age range can be overcome
with 4 weeks of bright light treatment and to gain infor-
mation on the relative benefit of different times of light
treatment.
Our aims were to compare the effectiveness of morning,
mid-day, and evening light treatments, individualized
according to clinical and actigraphic assessments, in cor-
recting circadian disturbances. Also, the trial sought to
demonstrate greater improvements in mood and sleep
among those volunteers receiving 4 weeks bright light as
contrasted to placebo.
Methods
Recruitment from July 2000 to December 2003 used
advertising and community presentations. Written
informed consent was obtained from each participant
prior to the start of the study, in accordance with the
guidelines set forth by the Declaration of Helsinki. The
study protocol and consent form were approved by the
UCSD Human Research Protection Program. In addition,
those participants who were being treated for depression
by either a physician or counselor were requested to
obtain the written agreement of the therapist for the
study, to assure that there was no interference with ongo-BMC Psychiatry 2005, 5:41 http://www.biomedcentral.com/1471-244X/5/41
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ing treatment and treatment responsibility. Patients were
encouraged to continue ongoing treatment during the
study, with the assumption that psychotherapy and med-
ication effects over an interval of 4 weeks were likely to be
small and randomized between groups.
After signing written informed consent, volunteers, ages
60–79 years, with significant depressive complaints were
evaluated for the randomized clinical trial. An intake
assessment questionnaire included questions concerning
depressive symptoms, the Geriatric Depression Scale
(GDS) [41], the Horne-Östberg Morningness-Evening-
ness Scale [42], questions concerning sleep, questions
concerning time in daylight, and questions concerning
medication use and current illnesses. The Structured Clini-
cal Interview for DSM-IV Axis I Disorders (Non-patient Edi-
tion)  [43] was administered during the baseline week,
prior to randomized treatment. For enrollment in the
study, a GDS score of 11 (indicating probable major
depression) [41] was required. This cut-off has 81% sensi-
tivity and 61% specificity for DSMIII-R major depression.
Meeting full DSM-IV criteria for current major depressive
disorder was not required, because many aging depressed
people are significantly troubled by minor depressive dis-
orders without meeting criteria for major depressive disor-
der [44]. Any lifetime history of mania required exclusion
of the potential volunteer, as a history of mania appears to
predict a greatly increased risk of a manic switch during
bright light treatment [45]. It may be assumed that almost
all aging depressed volunteers will offer sleep complaints.
The purpose of the sleep questions was to identify symp-
toms suggestive of circadian sleep phase disorders, such as
evening drowsiness or prolonged sleep latency, early
awakening or tending to awaken late, which might suggest
particular responsiveness to bright light treatment. These
symptoms were evaluated to select the optimal treatment,
and their presence suggested that the volunteer was a good
candidate for study recruitment. In contrast, symptoms
strongly suggestive of sleep apnea such as obesity, loud
snoring, and choking and gasping during sleep were con-
tra-indications to selection, as light is not known to be
useful for depressive symptoms related to breathing disor-
ders in sleep. The questions concerning daylight exposure
enabled us to avoid volunteers who were outdoors so
much that light treatment had little to add (e.g. outdoors
for more than an hour during times of potential light trig-
gered circadian rhythm shifts, that is morning or evening
hours). Throughout the five weeks of study, subjects con-
tinuously wore an Actillume wrist monitor (Ambulatory
Monitoring Inc., Ardsley, NY) to record movement and
light exposure.
Automated sleep scores were obtained from these records
using a previously validated algorithm [46,47]. Available
Actillume sleep measures for the night intervals in the
baseline week (an average of 6.8 nights) and the final
treatment week (an average of 6.7 nights) were averaged.
Sleep parameters at baseline were contrasted among the
groups assigned to bright and dim light in the morning,
midday, or evening, in two-way factorial ANOVA. Further,
sleep parameters at the end of treatment were likewise
contrasted, using the baseline values as a covariate.
Volunteers began placebo treatment during the initial
baseline week of the study. The purposes of placebo treat-
ment during the baseline week were to identify placebo-
responders, to test the volunteer's compliance, and to col-
lect baseline data. A member of the research staff visited
the volunteer's home bringing a modified Sunbox light
enclosure containing two red LED light sources (Enerlight
Corp. Model ENS2000), producing less than 10 photopic
lux of red light measured at 18" by a photometer pointed
towards the center of the diffuser (See Figure 1). The vol-
unteer was asked to sit in front of this dim-red-placebo
light box for 60 minutes, at mid-wake, for the baseline
week of the study. Mid-wake, determined from the ques-
tionnaires, was half-way between out-of-bed time and
lights-out time.
If a volunteer's GDS score dropped 20% or more from the
first day to the last day of the baseline week, the volunteer
was dropped prior to randomization. This aspect of the
design followed the general principle of clinical trial
design that better contrasts between active and placebo
treatments can often be obtained if early placebo-
Spectrophotometric measures of illumination are shown  comparing daylight with the white and red treatment lights Figure 1
Spectrophotometric measures of illumination are shown 
comparing daylight with the white and red treatment lights. 
Sunlight was measured with the photometer pointed 
towards the horizon (and shaded from direct sun) near noon 
on a clear sunny day (32.85 North latitude, 2/2/05). White 
light was measured at 18" with the photometer oriented 
towards the center of the box. The red light was measured 
with the photometer adjacent to the diffuser, because at 18" 
the illumination was too dim to be plotted on the same scale. 
The irradiance scale was arbitrary (uncalibrated) but identical 
for the three measures.
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responders are eliminated. As a courtesy to those subjects
who were dropped, they were permitted to continue with
the dim-red-placebo light box for 4 weeks if they wished.
Volunteers underwent baseline circadian assessment dur-
ing the week of dim-red-light placebo treatment. The
investigators predicted the best-choice timing for each
volunteer, in advance of treatment randomization, using
subjective questionnaire, sleep log data and the Actillume
recordings. Evening bright light was selected as the best
choice for volunteers who reported that they were falling
asleep in the evening excessively before going to bed or
who found themselves going to bed earlier than desired,
who complained of early awakening, or whose baseline
light-activity recordings indicated that they had these
problems. Conversely, early morning bright light was
selected for volunteers who reported that they had trouble
falling asleep at their desired bedtime, had a long sleep
latency, had trouble waking up in the morning or whose
baseline light-activity recordings suggested a delayed sleep
phase. Mid-day bright light was selected for volunteers
who reported no symptoms suggestive of a circadian
sleep-phase disorder, who reported mixed symptoms
which did not segregate into a consistent pattern sugges-
tive either of advance or delay, and whose light-activity
recordings gave no persuasive indication of a circadian-
sleep-phase disorder. Where choice of assignment seemed
inconclusive, the investigators sought to assign volunteers
to equalize the numbers receiving morning, mid-day, and
evening treatment. Utilization of placebo groups with
each timing was necessary to control for the different sleep
times of those assigned to the different treatment timings
and for the behavioral influences of sitting in front of light
boxes at different times of day.
Having been assigned one of three treatment times in
advance, placebo non-responders within each assigned
treatment time were then randomized into one of 2 treat-
ment groups: A) 8,500 lux bright white light (model: Sun-
Ray, Sunbox, Gaithersburg, MD) or B) 10 lux dim-red-
light placebo. Randomized assignment within blocks was
stratified for time-of-treatment, age below or ≥ 68 years,
and baseline GDS score below or ≥16 using computerized
randomization and sealed envelopes.
To test the benefits of partial sleep deprivation, on the
final night of baseline, we asked volunteers to awaken
themselves 4 hours after going to bed and to remain
awake for the second half of the night. They were asked to
call our telephone answering machine every half hour to
confirm that they were awake during that time period. In
a previous study, we found such home sleep deprivations
work well without complication [39]. An additional GDS
rating was completed at the usual time of awakening after
this half-night sleep deprivation.
As reviewed by Eastman [48], the issue of placebo
responses has been a serious problem in clinical bright
light studies, though the placebo problem has been negli-
gible in studies of the physiologic effects of light. We have
employed dim red light as a placebo, reasoning that
because the light was dim and because the red part of the
spectrum is relatively inactive biologically [49], there
would be no substantial effect. Many subjects consider
bright white fluorescent light to be glaringly ordinary,
whereas the red light may appear more special. The inves-
tigators find no controlled evidence that dim-red-light is
anything but placebo. Fortunately, claims by others of
red-light benefits allowed us to tell volunteers, without
deception, that some people think that red light is active
(even though we do not agree). In this way, we attempted
to maintain the best possible subject blind to the treat-
ment expectation.
To assess subject perception of treatments, an expectation
rating was obtained at the beginning of the study and at
the end of treatment. This consisted of a 100 mm visual
analog scale for the expectation for both sleep and mood
improvement. The initial rating was obtained after the
subject was randomized and had seen the light they
would be using but before the first actual treatment. A
final assessment was obtained on the last day of the study.
During the baseline (placebo) week, the volunteer com-
pleted sleep-activity logs daily and continuously wore an
Actillume to monitor baseline sleep-wake patterns and
baseline illumination patterns. The GDS [41] was
obtained on the first and last days of the baseline week.
Fractional urine samples supplemented by limited saliva
collections were collected during baseline and final weeks
to characterize the circadian phase of the subject's mela-
tonin rhythms.
Urinary excretion of the major melatonin metabolite, 6-
OH-melatonin sulfate (6-sulphatoxymelatonin or aMT6s)
was used as the primary phase marker of the endogenous
circadian pacemaker. For a 24-hour period prior to treat-
ment and another at the end of four weeks of treatment,
volunteers collected each fractional urine specimen,
measured and recorded the time and volume, and froze
duplicate 2 cc vials for assay. On the same occasions, from
4 hours before until bedtime and again from wake-up
until 4 hours after wake-up, the volunteer collected and
recorded the time of hourly saliva samples for a total of 5
evening samples, and 5 morning samples. Saliva samples
were collected to provide a potentially more accurate
measure of the onset and offset of melatonin secretion
than could be interpolated from aMT6s excretion.
Urinary aMT6s was assayed using 96 well ELISA kits
(Bühlmann Labs, EK-M6S) purchased from ALPCO, Ltd.BMC Psychiatry 2005, 5:41 http://www.biomedcentral.com/1471-244X/5/41
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(Windham, NH), a competitive immunoassay that uses a
highly specific rabbit anti-6-sulfatoxymelatonin antibody
and a second antibody capture technique. Assay perform-
ance has been extensively validated by the manufacturer
and results correlate well with the Arendt (Stockgrand,
Ltd) RIA (r = 0.987). Saliva samples were collected using
polyester-swab Salivettes (Sarstedt, Numbrecht, Ger-
many), centrifuged, and stored at -70°C. until assay. Sam-
ples were pretreated and assayed using Bühlmann
laboratories Direct Saliva Melatonin ELISA kits (EK-DSM,
ALPCO, ltd., Windham, NH).
Reliable estimates of aMT6s acrophase, onset and offset
require a clear circadian pattern that is free of major irreg-
ularities. To ensure reliability, we examined all excretion
curves visually to record an overall quality score for each
24-hour profile. This evaluation, blind to all other infor-
mation on participants, was based mainly on the shape
and completeness of the ng/h curve, but agreement
between ng/h and ng/ml temporal patterns, regularity of
the baseline, and reliability of the patient log were also
considered. Based on this evaluation, the present analyses
used 48 profiles from week 1 and 43 profiles from week 5
excluding 24% for poor quality (15 and 14 respectively).
Aside from the above considerations, data were unavaila-
ble (assays were not performed) for 26% of cases due to
the poor quality of the home collection or the loss of crit-
ical samples.
The aMT6s excretion rate for each urine sample was com-
puted and transformed into 5 min epoch data and the
resulting time series data were imported into Action3 soft-
ware (Ambulatory Monitoring Inc., Ardsley, NY), where
they were aligned with activity, sleep and illumination
data and further checked for accuracy. Then 24-hour least-
squares cosine fits were computed for each aMT6s collec-
tion, yielding mesors and acrophases. To estimate the
duration of nocturnal aMT6s excretion, the onset and the
offset of the excretion were estimated by interpolation of
times at which the excretion rate (ng/h) crossed the mesor
level. The time of onset of aMT6s excretion was estimated
as the upward crossing and offset as the downward cross-
ing of the mesor level. The aMT6s duration was defined as
the interval between onset and offset times.
Salivary melatonin data were rated for reliability follow-
ing guidelines similar to those used for urinary aMT6s,
and poor quality data were eliminated from further anal-
yses. Concurrently, where possible, onset was defined by
the first data point in the evening that was elevated above
a subjectively viewed baseline and was preceded by at
least one point at or below that value. Similarly, offset was
defined by the last data point in the morning that was ele-
vated above the baseline and was followed by at least one
point at or below baseline. Values used were an average
from two blind raters. Due to problems with the quality
of home collected saliva data, and some failed assays,
good quality saliva melatonin data were available from
only 28 collections in week 1 and 35 collections from
week 5.
The primary test of the light treatment in correcting circa-
dian phases was a contrast of the phase dispersion of
aMT6s acrophases in the bright-light-treated group vs. the
placebo group after 4 weeks of treatment, to test the
hypothesis that light treatment reduces dispersion of cir-
cadian phases. This contrast was computed by calculating
the median acrophase of each group. Then, for each sub-
ject in the trial, the [absolute value] deviation of each
acrophase from the group median was computed pre- and
post-treatment (d1 and d2), and the change in deviations
was calculated (D = d2 - d1).
In addition to daily log sheets used to record activity, sleep
behaviors, and visual analog self-ratings of mood, the
subjects completed a weekly GDS and a Systematic Assess-
ment for Treatment Emergent Events (SAFTEE) symptom
scale [50]. Further mood measurements were made at
baseline and end-of-treatment using the SIGH_SAD_SR, a
self-rating form of the Hamilton Depression Rating Scale
(HDRS) which includes atypical items previously shown
to be responsive to light treatment [51]. Additionally,
when a graduate student, blind to treatment, was availa-
ble, an HDRS interview was administered at baseline and
near the last day of the study.
Four weeks of treatment were carried out with weekly
symptom assessments and continuous wrist recordings of
activity and illumination exposure. The investigators vis-
ited subjects weekly to assure their safety and their com-
pliance with the study, to administer and collect rating
forms, and to transfer data from the Actillume recorders.
A final symptom and circadian assessment was completed
in the last 48 hours of the 4-week randomized treatment.
Two-week, 4-week and 3-month follow-up assessments
were obtained.
Records from the Actillume monitor indicating total activ-
ity, sleep-wake, log10[lux], and total lux were fitted to
cosine curves for each subject. The mesors or fitted cosine
means were examined, as well as the acrophases which
indicate the time of day of the fitted peak.
Healthy controls
Control subjects were recruited over the same interval as
depressed subjects. Volunteers who did not have a history
of depression were invited to participate as healthy con-
trols. The informed consent and screening procedures
were similar to those for depressed subjects. If qualified,
the volunteers wore an Actillume monitor for 48 hours.BMC Psychiatry 2005, 5:41 http://www.biomedcentral.com/1471-244X/5/41
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During this period they collected urine and saliva samples
over 24 hours in the same manner as the depressed sub-
jects.
Results
Based on power analysis, it was our intent to study 150
subjects over a five year period. After three and one-half
years, an interim data analysis did not detect any trend
towards a benefit from bright light (though a minimal
trend appeared in the final results below). We convened
an informal data safety and monitoring board to deter-
mine if continuing to collect data would be justified.
Because demonstration of a significant light treatment
benefit had become very unlikely, the board recom-
mended discontinuing the study. Results after early termi-
nation are presented below.
Signed consents for 191 participants were obtained to
conduct screening. Of these, 119 subjects met criteria for
enrollment, of which 81 completed the protocol. About
one third of the 119 subjects responded to placebo light
and were dropped during the first week of the study, prior
to randomization. There were 7 dropouts for other rea-
sons, before randomization. Among these reasons were:
family emergencies, discomfort with the research protocol
and equipment, and a decision not to continue for lack of
motivation. There were 2 dropouts after randomization:
both were due to medical health issues, unrelated to the
research, which required hospitalization. One had
received bright light and the other received dim light.
There were 34 male and 47 female subjects who com-
pleted the study. Bright light treatment was completed by
41 subjects, and 40 received dim red light. The mean age
for the completers was 67.7 years (SD = 5.45) and ranged
from 60 to 79.
Of the 81 subjects who completed the study, 24 were
being seen by a psychotherapist during research treat-
ment. Of these 24, 12 received bright light and 12 received
dim light. In all 24 cases, treatment was stable during the
study. Medication usage for the sample was as follows;
Antidepressants = 30 (15 bright light, 15 dim light),
Antianxiety = 11, Cardiac = 16, Antihypertensive = 25,
Analgesic = 20, Hypnotic = 8, Thyroid = 15, Hormone
Replacement Therapy = 22, Diabetes Drugs = 8 choles-
terol-lowering drugs = 14. Nineteen subjects received both
psychotherapy and psychiatric medication: 9 received
bright light and 10 received dim light. Seven of the bright
light subjects and 7 of the dim light subjects remained sta-
ble on their treatment regimen during the study. Two sub-
jects receiving bright light had medication changes and 3
dim light subjects had medication changes, without any
consistent patterns. Among all 81 subjects, those patients
who were not taking antidepressant medication experi-
enced nonsignificantly greater mood improvement from
light treatment as measured by the GDS (p = .124),
HDRS17 (p = .150) and, HDRS21 (p = .146). Thus less
than half of our sample subjects were receiving psycho-
therapy and/or antidepressant medication. They repre-
sented a broad spectrum of depressed patients which
ranged from long term chronic conditions with multiple
episodes to single events which both did and did not meet
criteria for Major Depressive Disorder. We obtained this
sample deliberately as we wished to test the general appli-
cability of light therapy for elders with depressive symp-
toms.
Based on the SCID interviews, Axis I diagnoses for the
sample were as follows; Major Depressive Disorder 57,
Minor Depressive Disorder 14, Adjustment Disorder 2,
Schizoaffective Disorder 1, and Mood Disorder due to a
General Medical Condition with depressive features 1.
None of the subjects met criteria for Seasonal Affective
Disorder. Five subjects had GDS ≥11 but did not meet
SCID criteria for any Axis I diagnosis.
For the 81 subjects who completed the protocol, light
treatments were randomized and stratified as shown in
Table 1. Groups assigned to active and placebo light treat-
ment were balanced in age and severity overall and by
time-of-day of treatment. Expectations for sleep and
mood effects of light treatment are shown in Table 2.
Repeated-measures MANOVA showed no difference in
the sleep and mood expectations between the bright and
dim treatment groups either before or after treatment, sug-
gesting that the dim red placebo induced balanced expec-
tations.
Sleep changes
As might be anticipated from the phase-typing, subjects
assigned to morning, midday, and evening light went to
bed at 00:03, 23:12, and 22:49, respectively (p < 0.05).
Similarly, they got out of bed at 08:14, 07:21, and 07:09
respectively (p < 0.06). Further, those treated with bright
light got out of bed an average of 37 min. earlier (p <
0.06), regardless of treatment timing and without signifi-
cant interaction with treatment time. There was no signif-
icant effect of randomized treatment assignment on time
of going to bed or getting out of bed, nor did total time in
bed vary significantly by treatment. The data for times of
sleep onset and sleep offset within the nocturnal periods
had similar trends. The total amount of Actillume-esti-
mated sleep was balanced at baseline and not significantly
affected by treatment assignment. The baseline, initial
week, estimate of total sleep during the nocturnal period
was 327 minutes. During the final week the estimate of
total sleep during the nocturnal period was 330 minutes.
The sleep efficiencies for the initial week and the final
week were 70.8 and 72.6 respectively. Wake After Sleep
Onset (WASO) did not vary by treatment time or rand-BMC Psychiatry 2005, 5:41 http://www.biomedcentral.com/1471-244X/5/41
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omization at baseline, but controlled for the baseline
value, there was a marginal interaction of randomization
with time of treatment at the end of treatment (P < 0.08),
perhaps indicating that morning bright light tended to
decrease WASO. However, the number of awakenings
during the night and the sleep latency did not vary signif-
icantly either at the beginning or end of treatment by ran-
domization or treatment timing.
Mood improvement
Mean mood scores for the different groups at each meas-
urement point are shown in Tables 3 and 4. There was lit-
tle improvement in mood after 1/2 night of wake therapy
(Table 3). Seventy-one subjects had some usable acti-
graphic data for week one and week two, but 10 were
missing part of these data. Approximately 85% of the sub-
jects phoned in every 30 minutes during the wake therapy
period. Nine of these 71 subjects either did not attempt to
wake early or were not able to remain awake for a signifi-
cant portion of the planned wake therapy period. Accord-
ing to actigraphic scoring, twenty-four of 71 (34%) were
able to remain 100% awake for the entire wake therapy
period (4 hours); however, only 12 of these (17 % of the
total) also remained 100% awake for the rest of the day.
The mean percentage awake during wake therapy period
for those attempting wake therapy was 87.5% (SD = 15.9,
N = 62), whereas the mean percentage awake on a com-
parison night in the previous (baseline) week was 39.1%
(SD = 20.8, N = 61). The mean percentage awake for the
full wake therapy day (20 hours) was 88.2% (SD = 32.9,
N = 61). There was no significant Spearman correlation of
wake therapy compliance (percent awake during the wake
therapy period or during the full wake therapy day) with
the change in mood from baseline to the morning after
wake therapy. Likewise, there was no significant correla-
tion between wake therapy compliance and GDS mood
score changes one week later, either for the entire sample
or for bright or dim light-treated groups separately.
Subjects' moods improved under both treatments at all
times of day by treatment week 4. Combining the 3 times
of day, GDS scores improved from 19.46 to 14.39 in those
treated with bright light and from 19.50 to 15.28 in those
treated with placebo dim light. However, there were no
significant differences in treatment effects nor were there
time-by-treatment interactions. There was no significant
treatment effect for any treatment time. The average
HDRS17 (extracted from the self-rated SIGH-SAD-SR)
improved by 6 points. Combining the 3 times of day,
HDRS17 scores improved from 16.85 to 11.07 in those
treated with bright light and from 17.55 to 11.28 in those
treated with dim light. Again there were no significant
treatment effects or time-by-treatment interactions. Blind
HDRS17 ratings, when available, were consistent with the
self-rating (HDRS17) scores. A power analysis indicated
approximately 81% power to detect an effect size of 0.32
in either the GDS or self-rated HDRS.
Adverse reactions
Participants experienced no psychiatric hospitalizations,
suicide attempts, or deaths during the study. However,
one participant who dropped out while receiving bright
light treatment died in the hospital due to late stage
emphysema, 3 months after leaving the study. There were
no incidents of mania or hypomania during the light
treatment.
The weekly SAFTEE physical symptom inventory was
examined for adverse reactions to both light treatments
using Wilcoxon's Signed Rank Test. To improve the stabil-
ity of measurement, the 94 individual symptoms were
grouped into 17 SAFTEE-defined categories. The results of
these group tests are contained in Table 5. The symptom
groups for Head, and Other improved with bright light
while Urination worsened, and with dim light, Mouth
and Teeth improved while Urination, and Genital/Sexual
Functioning worsened.
Testing with the Mann-Whitney U-test showed there were
no significant differences in change scores (baseline
minus post treatment) of the 94 individual SAFTEE items
between bright and dim treatment. Of the 17 symptom
groups, only one showed a significant treatment differ-
ence, a greater improvement in "Other" in the bright light
group than in the dim light controls, (N = 47, p = 0.04,
uncorrected for multiple testing.) The "Other" category
contains a large number of mood related items (see Table
6).
Measures of urinary aMT6s and saliva melatonin
The aMT6s mesors were not significantly different
between patients and controls nor between genders, but a
marginal interaction was observed in log10  [mesor]
between gender and patient vs. control (DF = 1,88, F = 4.3,
p = 0.043), with male patients having over 4 times the
aMT6s mesor, whereas female controls had slightly higher
mesors. Baseline salivary melatonin onsets and offsets
and aMT6s acrophases, onsets and offsets tended to be
later among patients than controls, but none of these dif-
ferences were significant after adjustment for age and gen-
der, nor were durations of secretion or excretion different.
At baseline, aMT6s acrophases did not differ by treatment
or time of treatment or their interaction, nor did acro-
phase shifts from baseline to the end of treatment. How-
ever, in females aMT6s acrophase was more phase
advanced during randomized treatment (p < 0.05). Sali-
vary melatonin offsets (not onsets) showed significant
treatment, time of treatment, and interaction effects
(greatest advance in morning-treated subjects receiving
bright light), but the high-quality usable cases in each cellBMC Psychiatry 2005, 5:41 http://www.biomedcentral.com/1471-244X/5/41
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were as few as 2 (See Table 7). The Horne-Östberg Morn-
ingness-Eveningness scores for patients and healthy con-
trols are reported in Table 7.
Correcting circadian phases
Testing the hypothesis that light treatment reduces disper-
sion of circadian phases did not show any statistically sig-
nificant difference in the pre- and post-treatment
deviations (d1 and d2) from group median acrophases for
aMT6s, sleep or activity. Light acrophase dispersion
showed a significant effect of treatment time (p = .017).
The difference in light acrophases was independent of the
light condition (dim vs. bright). Therefore, it was more
consistent with spontaneous regression than any treat-
ment effect.
Sleep-wake acrophases
For the five-week study period, regression slopes were cal-
culated for the acrophase changes in light, activity and
sleep. These slopes were compared (ANOVA) to differ-
ences between the week 1 and week 5 acrophases. The
regression slope of the 5 weeks was similar to the week 1
minus week 5 results (data not shown).
There was a significant (p = 0.001) advance in illumina-
tion acrophase across the three treatment times, from
baseline to the end of treatment, for the bright light group
and not for the dim light group. Overall, the bright and
dim light conditions did not differ significantly in light
acrophase. The illumination acrophase change, week 1
minus week 5, showed a significant interaction between
treatment time and treatment condition (p = 0.001) in the
expected directions: that is, the group treated with bright
light in the morning advanced acrophases more than the
placebo morning group, whereas this did not occur with
evening treatment. This demonstrates that light acrophase
shifted in the expected direction in response to the morn-
ing bright light treatment. This change in light acrophase
was associated with significant differences in the activity
(p = 0.003) and sleep (p = 0.001) acrophase shifts
between the bright and dim treatment groups but no sig-
nificant treatment versus time interaction.
Although an objective measure of compliance was not
determined, observation of the light records from the
Actillume data suggested a high degree of compliance
with bright light treatment. Dim light treatment could not
be detected from the Actillume data. The self-reports of
Table 1: Randomization of Light Treatment Time and Stratification by Age and Depression Severity
Time of Light Treatment Bright Dim Total
Morning 13 15 28
Mid-Wake 15 16 31
Evening 13 9 22
Total 41 40 81
Age-Depression Severity Group
Age<68, GDS<16 448
Age<68, GDS ≥16 18 16 34
Age ≥68, GDS<16 661 2
Age ≥68, GDS ≥16 13 14 27
Total 41 40 81
Table 2: Expectations for Improvement in Sleep and Mood
100 mm Visual Analog Scale, 0 = Worse 100 = Better
Measure Sleep Mood
Light Bright Dim Bright Dim
Time Initial Final Initial Final Initial Final Initial Final
N 40 40 38 38 40 40 38 38
Mean 71.4 71.2 68.7 63.5 72.2 73.4 72.3 68.3
SD 15.3 14.7 13.5 21.6 15.5 13.4 15 21BMC Psychiatry 2005, 5:41 http://www.biomedcentral.com/1471-244X/5/41
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treatment time and duration were almost entirely consist-
ent with instructions. The low dropout rates and the com-
pliance of participants with wearing Actillumes and
completing logs and questionnaires also suggested that
compliance with treatment was probably high.
Healthy controls
The healthy control group was active earlier, slept earlier,
and reported significantly greater morningness but
received less light than the depressed group at baseline
(see Table 9).
Discussion
Apart from an advantage on one scale of the SAFTEE side
effects inventory (which would not be significant by Bon-
ferroni criteria), bright light treatment had no advantage
over dim placebo light. The beneficial effects found in the
study might be attributed to several factors that were com-
mon to the treatment and control groups. The "placebo"
effect, chiefly positive expectations, positive staff contacts,
and spontaneous remission may have contributed to pos-
itive responses. Weekly visits, even with minimal social
interaction, could have a positive effect. In addition, the
social structure and regularized sleep provided by the pro-
tocol might be beneficial. An hour a day engaging in a
treatment, thought to be helpful, may have induced a
reduction in depressive symptoms. Participants with
ongoing pharmacologic or psychotherapeutic treatment
(possibly associated with greater severity or chronicity of
illness) improved somewhat less than other participants,
so such treatment was probably not a substantial con-
found.
As a result of the phase-typing treatment assignment, a
group going to bed and arising later were assigned to
morning light, and a group going to bed earlier were
assigned to evening light, with the midday group interme-
diate. There was little evidence for the anticipated effects
of the bright light treatment, which had been expected to
alter sleep timing. Likewise, the effects of bright light treat-
ment on melatonin phase were modest. Therefore, we
would suspect either that these depressed elders were
resistant to bright light effects or that we were less success-
ful in obtaining compliance than we realized.
Even though this study is among the longest treatment tri-
als investigating the effects of light on depression, it may
be that the duration of treatment was not sufficient for
this age group. A longer period may be needed for an eld-
erly population with chronic depressive symptoms.
Although the use of home based treatment may have
given rise to less treatment compliance, these subjects did
not require hospitalization clinically. Inpatient studies of
light treatment have demonstrated antidepressant effects.
To be cost effective for patients with milder depressions,
light treatment must be feasible in the home. If compli-
ance was a problem in our trial, it would probably be a
similar problem in clinical application of this treatment
for this age group.
Table 3: GDS Scores by Week by Light Condition and Treatment Timing: Mean (SD) N
Time Light Morning Mid-day Evening Total
Bright Dim Bright Dim Bright Dim Bright Dim
Baseline start 21.23 
(6.08) 13
21.00 
(4.47) 15
18.73 
(2.91) 15
19.50 
(4.43) 16
18.54 
(5.63) 13
17.00 
(4.27) 16
19.46 
(5.01) 41
19.50 
(4.56) 40
End of baseline week 21.77 
(5.85) 13
20.33 
(4.53) 15
18.93 
(3.41) 15
19.63 
(4.83) 16
18.62 
(5.61) 13
17.89 
(5.09) 9
19.73 
(5.07) 41
19.50 
(4.74) 40
After wake therapy 21.67 
(5.68) 9
19.43 
(6.73) 14
18.00 
(5.31) 12
18.00 
(5.85) 13
16.60 
(5.97) 10
17.14 
(4.14) 7
18.61 
(5.82) 31
18.41 
(5.85) 34
Treatment Week 1 20.00 
(5.55) 13
19.33 
(7.69) 15
18.20 
(4.06) 15
16.94 
(3.99) 16
15.08 
(8.41) 13
15.11 
(5.11) 9
17.78 
(6.35) 41
17.43 
(5.95) 40
Treatment Week 2 20.08 
(6.22) 13
18.60 
(7.60) 15
16.21 
(5.69) 14
14.38 
(5.30) 16
14.75 
(8.07) 12
12.33 
(5.45) 9
17.05 
(6.87) 39
15.50 
(6.65) 40
Treatment Week 3 18.85 
(6.50) 13
18.50 
(6.44) 14
15.00 
(5.41) 15
14.81 
(5.97) 16
13.23 
(6.66) 13
13.00 
(7.05) 9
15.66 
(6.45) 41
15.72 
(6.61) 39
Treatment Week 4 17.38 
(6.96) 13
18.67 
(7.79) 15
14.07 
(6.06) 15
13.81 
(5.60) 16
11.77 
(7.00) 13
12.22 
(6.53) 9
14.39 
(6.88) 41
15.28 
(7.07) 40
Two-Week follow-up 16.25 
(7.96) 12
16.00 
(7.72) 11
13.69 
(5.41) 13
11.85 
(5.80) 14
11.80 
(6.66) 10
12.13 
(8.41) 8
14.03 
(6.77) 35
13.30 
(7.18) 33
Four-Week follow-up 17.25 
(6.54) 8
14.00 
(9.03) 9
12.77 
(5.69) 13
13.08 
(5.27) 13
13.55 
(6.25) 11
10.25 
(8.40) 8
14.16 
(6.18) 32
12.60 
(7.29) 30
3-Month follow-up 14.00 
(9.47) 8
18.14 
(9.58) 7
15.91 
(5.26) 11
11.21 
(5.74) 14
16.29 
(6.97) 7
11.60 
(9.63) 5
15.42 
(6.99) 26
13.15 
(7.97) 26BMC Psychiatry 2005, 5:41 http://www.biomedcentral.com/1471-244X/5/41
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The antidepressant response to placebo light treatment in
this study was similar to that reported for placebo in drug
studies [52]. However, placebo response is significant and
needs to be considered as a confound in antidepressant
light treatment studies. Removing placebo responders is
common in pharmacology trials but has not commonly
been practiced previously in light studies. Removing pla-
cebo responders from sample groups may decrease the
placebo effects in the randomization portion of clinical
trials, but even so the subsequent placebo effects were
quite large. It is not evident that removal of placebo-
responders was advantageous in this design. Exclusion of
bipolar participants effectively prevented hypomanic
adverse events, but possibly bipolar depressives are more
light responsive.
Treatments were balanced by age and severity of depres-
sion, validating that the stratification randomization pro-
cedures were successful. The design was successful in
balancing expectations between bright light and placebo.
The similarity of blind-observer HDRS ratings with self-
rating results tends to reduce concern with the blinding
issue.
Only a small minority of elderly participants in this study
were able to wake themselves up in the middle of the
night and remain entirely awake until the next bedtime at
home. Because study participants had a very low dropout
rate and complied very well with other aspects of the pro-
tocol, it would appear that the poor compliance was due
to the difficulty of the assignment rather than to poor
motivation. The small number of subjects who were able
Table 4: HDRS Scores by Week by Light Condition and Treatment Timing: Mean (SD) N
Time Light Morning Mid-day Evening Total
Bright Dim Bright Dim Bright Dim Bright Dim
Self Report HDRS 17-Baseline 19.76 
(8.46) 13
19.20 
(6.05) 15
16.80 
(6.12) 15
17.31 
(5.53) 16
14.00 
(6.22) 13
15.22 
(3.38) 9
16.85 
(7.18)41
17.55 
(5.44) 40
Self Report HDRS 17-Final 15.46 
(8.49) 13
13.27 
(5.78) 15
10.87 
(5.87) 15
10.38 
(4.79) 16
6.92 
(4.13) 13
9.55 
(7.92) 9
11.07 
(7.12) 41
11.27 
(6.02) 40
Blind HDRS 17-Baseline 21.14 
(7.86) 7
21.60 
(6.35) 10
18.50 
(5.40) 10
18.20 
(7.30) 10
15.13 
(8.18) 8
16.40 
(3.78) 5
17.96 
(6.95) 27
18.89 
(6.35) 27
Blind HDRS 17-Final 16.00 
(8.74) 7
11.80 
(5.47) 10
10.70 
(4.74) 10
12.30 
(6.26) 10
6.62 
(5.24) 8
9.20 
(7.60) 5
11.15 
(7.01) 26
11.38 
(5.97) 26
Table 5: SAFTEE Symptoms, Mean Scores for Beginning and End of Light Treatment with Wilcoxon Signed Ranks Test
Light Condition Bright Dim
Symptom 
Category
Baseline Post Treatment p Baseline Post Treatment p
Head 5.62 4.92 .012 5.35 5.14 .065
Eyes 8.53 8.61 .404 8.76 8.27 .168
Ears 5.15 5.22 .791 5.14 5.53 .502
Mouth/Teeth 8.48 7.82 .193 8.41 7.28 .001
Nose/Throat 6.71 7.03 .297 6.58 6.12 .312
Chest 8.17 7.74 .683 7.71 8.00 .315
Heart 2.28 2.19 .276 2.69 2.55 .106
Stomach/
Abdomen
6.03 5.46 .080 5.37 5.00 .239
Bowel 8.64 8.40 .487 8.39 8.32 .790
Appetite 7.91 7.58 .394 7.69 7.66 .699
Urination 5.79 7.11 <.001 6.28 8.18 <.001
Gynecology 9.40 9.00 .854 8.91 9.75 .655
Genital/Sexual 8.31 9.64 .077 7.85 9.87 .004
Muscle/Bone 5.97 5.85 .573 5.25 4.94 .178
Walking/Moving 7.06 7.36 .271 7.21 7.74 .239
Scalp/Skin 5.76 5.70 .636 5.39 5.53 .120
Other 28.73 23.4 <.001 27.32 25.17 .091BMC Psychiatry 2005, 5:41 http://www.biomedcentral.com/1471-244X/5/41
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to successfully remain awake for the entire prescribed time
may explain why there was no detected antidepressant
benefit of the wake therapy. The literature suggests that
even a short nap may reduce the mood improvement
obtained from wake therapy [53]. Unfortunately, in this
age group, the tendency to fall asleep during the day was
surprisingly strong [54,55]. Home wake therapy may be
too difficult for elderly depressed patients. In addition,
there is not much of evidence that sleep deprivation is use-
ful in this age group [56,57]. Indeed, a recent study sug-
gested that in this age group, sleep deprivation may
actually interfere with antidepressant treatment [58],
which is a possible explanation for the lack of success of
this trial.
Tables 7 and 9 indicate that the rhythms of melatonin,
sleep, and activity all peaked later (were delayed) as com-
pared to the normal control group. Although this finding
is not consistent with the older theory that aging depres-
sives are phase-advanced, it is generally consistent with
more modern results in post-menopausal women [32,59].
Table 9 indicates that mesor illumination (the daily
amount of illumination) was significantly higher in the
depressed participants than controls, which indicates that
the relative baseline phase delay of depressives cannot be
ascribed to below-average light exposure. However, since
increased light exposure is generally associated with more
advanced rhythms (as was observed comparing the bright
light and placebo groups in this study), the results are con-
sistent with the possibility that these depressed patients
were subsensitive to circadian effects of light. The data in
Table 8 show that the morning and evening bright light
treatments tended to have the predicted phase-shifting
effects, but only to a quite modest extent not significant in
the interaction effects for activity and sleep. The lack of
greater phase-shifting effects related to the experimental
treatments provides an additional indication that either
these depressives may have been subsensitive to bright
light or their compliance may have been less than we real-
ized.
There was considerable overlap in baseline activity and
aMT6s phases among the groups assigned to morning,
mid-day, and evening bright light. Thus, our prospective
phase-typing was imperfect. Nevertheless, examining the
subgroups who were phase-typed correctly did not indi-
cate any better responses to the bright light treatment.
Conclusion
Antidepressant response to bright light treatment in this
age group was not statistically superior to placebo. No
timing of bright light treatment was significantly better
than placebo or consistently better in self-ratings and
blind ratings. There was minimal evidence for a relative
reduction of diverse SAFTEE complaints in the bright-
light-treated group. Contrary to what has been suggested
by previous light studies [15,27], the trend was for
evening light to appear at least as successful as morning or
mid-day light. Were it a statistically significant difference,
an advantage of evening light would be unexpected in a
group of depressed participants who are generally more
phase delayed than healthy individuals. We do not know
whether the lack of light response found in this study
might be associated with the age of the subject group, the
relative mildness and chronicity of their symptoms, inad-
equate duration of bright light treatment, perhaps unde-
tected compliance problems occurring in home
treatment, or some aspect of the trial design such as the
sleep deprivations. Considering the general evidence that
light treatment is useful for depression, including in this
Table 6: Mean SAFTEE "Other" Scores Before and After Light 
Treatment
Other, Baseline average – Bright 28.73
Other, Baseline average – Dim 27.32
Other, End-of-treatment average – Bright 23.39
Other, End-of-treatment average – Dim 25.17
Mann-Whitney (N = 47, p = 0.04, uncorrected for multiple testing)
Table 7: Timing of Saliva Melatonin and Urinary aMT6s at Baseline Mean (SD) N
Times are in decimal hours
Saliva Melatonin Depressed Healthy Controls Sig. (T-test, p)
Onset 21.48 (1.67) 28 20.36 (1.98) 22 0.16
Offset 8.76 (2.14) 32 8.78 (1.22) 16 0.873* unequal variance
Duration 11.19 (1.64) 25 11.75 (1.75) 15 0.574
Urinary aMT6s
Onset 23.95 (3.15) 48 22.22 (2.44) 28 0.015
Offset 9.72 (2.82) 48 8.70 (2.02) 28 0.099
Duration 9.75 (2.48) 48 10.48 (2.21) 28 0.201
Acrophase 4.25 (2.56) 49 3.36 (1.75) 28 0.107
Mesor (ng/hour) 652.12 (911.31) 49 485.40 (377.80) 28 0.36
Horne-Östberg 54.75 (11.45) 81 67.65 (9.38) 23 < 0.001BMC Psychiatry 2005, 5:41 http://www.biomedcentral.com/1471-244X/5/41
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age group, further testing with altered designs might be
fruitful.
Upon early termination of this study, a trial of green light
was initiated with somewhat more promising results.
These results are presented in a separate report .
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